Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
3
×
boston blog main
boston top stories
clinical trials
life sciences
national blog main
ally bridge group
bayer
big data analytics
biotech ipos
blackrock
casdin capital
cronos group
deals
diabetic nephropathy
dyne therapeutics
eventide asset management
fda
focal segmental glomerulosclerosis
ginkgo bioworks
goldfinch bio
hyperammonemia
irving investors
james collins
jay ghosh
liver diseases
metacrine
myotonic dystrophy type 1
national top stories
neurological diseases
nonalcoholic steatohepatitis
phenylketonuria
rare disease drugs
rare diseases
salk institute
san diego blog main
san diego top stories
schroeder adveq
software
What
company
3
×
medicines
3
×
drug
genetic
ipo
million
raised
analysis
bacteria
bio
biology
biotech
bioworks
bring
brings
called
comprised
develop
developer
developing
diseases
disorders
dyne
dyne’s
employing
engineered
ginkgo
goldfinch
kidney
lands
later
lead
living
muscle
muscular
new
preclinical
raises
ramp
rare
Language
unset
Current search:
medicines
×
company
×
boston
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Synlogic Lands $80M from Ginkgo to Ramp Up “Living Medicines” R&D
